

Mojave Therapeutics (Hawthorne, NY) has announced the appointment of **Brian H. Barber** as chief scientific officer and senior vice president, a newly created position. Dr. Barber was previously assistant vice president for immunology at Aventis Pasteur.

Mark Boulding has been named senior vice president, business development and legal, at PTC Therapeutics (South Plainfield, NJ). He was previously general counsel and executive vice president at MedicaLogic/Medscape. In addition, PTC announced that it has added **William Baird** as senior director of finance and strategy. Mr. Baird joins PTC from L.E.K. Consulting, where he was an engagement manager handling strategic and finance-based projects for biopharmaceutical companies.

Oxford GlycoSciences (Oxford, UK) has announced the appointment of **David Ebsworth** as chief executive officer. Dr. Ebsworth was most recently head of Bayer's worldwide pharmaceutical business group.

Caliper Technologies (Mountain View, CA) has announced the following management changes: co-founder and vice president of corporate development **Michael R. Knapp** has assumed the responsibilities of CEO, and executive vice president and chief financial officer **James L. Knighton** will become president. After a period of several months, both Dr. Knapp and Mr. Knighton will join the Caliper board. **Daniel L. Kisser** will become chairman of the board, relinquishing his roles as the company's CEO and president. At the same time, **David V. Milligan**, currently the chairman of the board, will become the vice chairman. In addition, Caliper has named **William C. Kruka** vice president of business development and **Bruce E. MacMillan** vice president and general counsel. Most recently, Mr. Kruka was senior manager of business development with Applied Biosystems Group, and Mr. MacMillan was vice president, general counsel and corporate secretary for Sugan.

R. Ian Lennox has been appointed to the board of directors of Stressgen Biotechnologies (San Diego, CA). Since April 2000 he has held the position of president and CEO of MDS Inc.'s drug discovery and development sector.

Affymax (Palo Alto, CA) has announced the appointment of **Daniel J. Levitt** to the position of chief operating officer and head of research and development. He joins the company from Protein Design Labs, where he had been president of research and development since May 2000.

Peter Myers has been named chief executive officer of Libraria (San Jose, CA). He has served as a member of the board of directors since October 2001, and was most recently executive vice president and site director of Deltagen Research Laboratories.

Iconix Pharmaceuticals (Mountain View, CA) has announced the appointment of **Jim Neal** as CEO, succeeding **Keith Bostian**, Iconix's founder. Mr. Neal was previously executive vice president, sales, marketing and business development for Incyte Genomics.

Barry L. Scott has joined Biopure (Cambridge, MA) as vice president of international business development. He has most recently served as vice president of business development, Europe, at Bristol-Myers Squibb. Biopure also announced the appointment of **Jo Anne Fladger** as director of clinical operations. Ms. Fladger most recently served as a clinical operations consultant with Wyeth-Ayerst.

Harold E. "Barry" Selick has joined Sofinnova Ventures (San Francisco) as a venture partner. Dr. Selick co-founded Camitro in January 1999 and served as president and CEO until its acquisition by Arqule in 2001. He was also vice president, research for Affymax Research Institute.

Inspire Pharmaceuticals (Durham, NC) has announced the appointment of **W. Leigh Thompson** as chairman of the board of directors, replacing **Terrance G. McGuire** of Polaris Venture Partners, whose term on the board and as chairman has expired. Dr. Thompson was formerly chief scientific officer for Eli Lilly and Co., and has served on Inspire's board since 1996. The company also announced the election of **Kip Frey**, a professor of the practice in entrepreneurial management and law at Duke University, to the board of directors and the promotion of **Gregory J. Mossinghoff** from senior vice president and chief business officer to the position of president.

SkyePharma (London) has announced the appointment of **Steven Thornton** as president of the company's research, development, and manufacturing facility for sustained-release injectable technology in San Diego, CA. He was formerly executive vice president of commercial development for Elan Pharmaceutical Technologies.

Syrrx (San Diego, CA) has named **David Weitz** vice president of intellectual property and general counsel. Mr. Weitz was a previously a partner at Wilson Sonsini Goodrich & Rosati, where he co-headed the firm's patent prosecution department.